Advancing evidence generation for oncology medical products
Advancing evidence generation for approved oncology medical products
Related Articles
Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
2024 Orphan Drugs: PDUFA Dates and FDA Approvals
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
Expert Urges Researchers to Challenge Dogma & Forge Novel… : Oncology Times
An abstract is unavailable.
BET Inhibitor Shows Encouraging Safety and Tolerability in Myelofibrosis | Blood Cancers Today
The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.
Early Alert: Endoscope Accessories Forceps/Irrigation Plug Issue
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program